A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin) in Healthy Adults
Phase of Trial: Phase III
Latest Information Update: 07 May 2014
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis Vaccines
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2013 Planned end date changed from 31 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 19 Jun 2013 New source identified and integrated (ClinicalTrials.gov; NCT01885117).